Genetic Technologies traded at $0.77 this Wednesday October 16th, decreasing $0.02 or 1.92 percent since the previous trading session. Looking back, over the last four weeks, Genetic Technologies lost 6.14 percent. Over the last 12 months, its price rose by 12.50 percent. Looking ahead, we forecast Genetic Technologies to be priced at 0.75 by the end of this quarter and at 0.70 in one year, according to Trading Economics global macro models projections and analysts expectations.
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.